Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2015
At a glance
- Drugs MK 2206 (Primary) ; Selumetinib (Primary)
- Indications Colorectal cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 10 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Jun 2014 Planned End Date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.